MedTrace Logo

Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study

NCT00371098 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 658

Last updated 2007-10-23

No results posted yet for this study

Summary

Background: Influenza vaccination is recommended in patients (pts) with cardiovascular disease, however there is a shortage of clinical studies proving its protective effect on clinical course of coronary artery disease (CAD). The aim of the study was to evaluate the effect of influenza vaccination on the incidence of coronary events in pts with CAD confirmed by coronary angiography.

Conditions

Interventions

BIOLOGICAL

Influenza vaccination: Influvac (SolvayPharma)

BIOLOGICAL

placebo influenza vaccine

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • National Institute of Cardiology, Warsaw, Poland

    lead OTHER

Principal Investigators

  • Andrzej Ciszewski, MD, PhD · 1st Dept of Coronary Artery Disease, Institute of Cardiology, Warsaw, Poland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Completion
2005-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371098 on ClinicalTrials.gov